The article reports on once-weekly injectable diabetes medication from drugmakers Amylin Pharmaceuticals Inc. and Eli Lilly & Co. The drugmakers are waiting for regulatory approval of their once-weekly injectable diabetes medication, Bydureon. Daniel Drucker, a diabetes researcher at the Samuel Lunenfeld Research Institute, says that the diabetes drugs not only lowers glucose but also tackles weight at the same time.